Patent Publication Number: US-2020297711-A1

Title: Pharmaceutical composition comprising fgfr selective tyrosine kinase inhibitor

Description:
TECHNICAL FIELD 
     The present invention relates to a pharmaceutical composition comprising FGFR selective tyrosine kinase inhibitor, specifically 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridine-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmaceutically acceptable salt thereof. 
     BACKGROUND ART 
     The compound represented by the formula (I): 
     [Chem. 1] 
     
       
     
     is known as 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide (hereinafter referred to as “Compound A”). It has been reported that Compound A has an inhibitory activity on fibroblast growth factor receptors (FGFRs) 1, 2 and 3 and has a cell growth suppressing activity in stomach cancer, lung cancer, bladder cancer and endometrial cancer (PTL 1) as well as in bile duct cancer (PTL 2) and in breast cancer (PTL 3). 
     CITATION LIST 
     Patent Literature 
     [PTL 1] US 2014-235614 
     [PTL 2] WO/2016/152907 
     [PTL 3] WO/2017/104739 
     SUMMARY OF INVENTION 
     Technical Problem 
     The relationship between the pharmacokinetics (hereinafter referred to as “PK”) of Compound A in human subjects and the therapeutically effective amount thereof to be expected has not been known. 
     In addition, although the structure of 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide (hereinafter referred to as “Compound B”) and the FGFR inhibitory activity thereof in preclinical model have been disclosed in PTL 1, it has not been known that when Compound A is administered to human subjects, Compound A is metabolized in the body to produce Compound B. The compound B is represented by the formula (II): 
     [Chem. 2] 
     
       
     
     Solution to Problem 
     It is an object of the present invention to provide a pharmaceutical composition comprising a therapeutically effective amount of Compound A or pharmaceutically acceptable salts thereof. 
     The present invention relates to the following 21 1&gt; to &lt;22&gt;. 
     &lt;1&gt; An oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said Compound A is 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridine-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide represented by Formula (I): 
     [Chem. 3] 
     
       
     
     &lt;2&gt; The oral dosage form of &lt;1&gt;, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     &lt;3&gt; The oral dosage form of &lt;1&gt;, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     &lt;4&gt; The oral dosage form of &lt;1&gt;, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     &lt;5&gt; The oral dosage form of &lt;1&gt;, wherein said oral dosage form at a single daily dose achieves a mean C max  of Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 4] 
     
       
     
     &lt;6&gt; The oral dosage form of &lt;1&gt;, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of Compound B of from about 2.7x10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 5] 
     
       
     
     &lt;7&gt; The oral dosage form of &lt;1&gt;, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 6] 
     
       
     
     &lt;8&gt; An oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said Compound A is 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridine-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide represented by Formula (I): 
     [Chem. 7] 
     
       
     
     &lt;9&gt; The oral dosage form of &lt;8&gt;, wherein said single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     &lt;10&gt; The oral dosage form of &lt;8&gt;, wherein said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     &lt;11&gt; The oral dosage form of &lt;8&gt;, wherein said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     &lt;12&gt; The oral dosage form of &lt;8&gt;, wherein said single daily dose achieves a mean C max  of Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 8] 
     
       
     
     &lt;13&gt; The oral dosage form of &lt;8&gt;, wherein said single daily dose achieves a mean AUC (0-t)  of Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 9] 
     
       
     
     &lt;14&gt; The oral dosage form of &lt;8&gt;, wherein said single daily dose achieves a mean AUC (0-inf)  of Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 10] 
     
       
     
     &lt;15&gt; The oral dosage form of &lt;1&gt; or &lt;14&gt;, wherein said oral dosage form is used for treatment of stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer. 
     &lt;16&gt; A method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said Compound A is 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridine-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide represented by Formula (I): 
     [Chem. 11] 
     
       
     
     &lt;17&gt; The method of &lt;16&gt;, wherein said single daily dose achieves C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to the human subject. 
     &lt;18&gt; The method of &lt;16&gt;, wherein said single daily dose achieves AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to the human subject. 
     &lt;19&gt; The method of &lt;16&gt;, wherein said single daily dose achieves AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to the human subject. 
     &lt;20&gt; The method of &lt;16&gt;, wherein said single daily dose achieves a mean C max  of Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects, and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 12] 
     
       
     
     &lt;21&gt; The method of &lt;16&gt;, wherein said single daily dose achieves a mean AUC (0-t)  of Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 13] 
     
       
     
     &lt;22&gt; The method of &lt;16&gt;, wherein said single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects and said Compound B is 6-(2-Methoxyethoxy)-N-methyl-5-((2-(4-(piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-1H-indole-1-carboxamide represented by Formula (II): 
     [Chem. 14] 
     
       
     
    
    
     
       BRIEF DESCRIPTION OF DRAWINGS 
         FIG. 1  shows plasma concentration profiles of Compound A following a single dose of Compound A. 
         FIG. 2  shows plasma concentration profiles of Compound A following repeated doses of Compound A. 
         FIG. 3  shows CT images of the patient with FGFR2 gene amplified diffused type gastric cancer before the administration of Compound A (left) and on Day 1 of Cycle 3 (right). 
         FIG. 4  shows percent change from baseline on Day 15 of Cycle 1 of PD markers. 
     
    
    
     Left: phosphate, middle: FGF23, and right: 1,25-dihydroxyvitamin D 3 . 
     DESCRIPTION OF EMBODIMENTS 
     I. Definitions 
     In order the invention described herein may be more fully understood, the following definitions are provided for the purposes of the disclosure: 
     The term “effective amount” means an amount of Compound A that is capable of achieving a therapeutic effect in a human subjective in need thereof. 
     The term “human subject” shall mean a normal healthy male or female volunteers and/or any individual that presents with clinical signs or symptoms of cancer. 
     The expression “bioequivalent” or “bioequivalence” is a term of art and is intended to be defined in accordance with Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition, which is published by the U.S. Department of Health and Human Services, and is commonly known as the “Orange Book”. Bioequivalence of different formulation of the same drug substance involves equivalence with respect to the rate and extent of drug absorption. The extent and rate of absorption of the test formulation is compared to a reference formulation in order to determine whether the two formulations are bioequivalent. The standard bioequivalence study is conducted in crossover fashion by extensive testing which includes administering single doses of the test and reference drugs to a number of volunteers, usually 12 to 24 healthy normal adults, and then measuring the blood or plasma levels of the drug over time. Detailed guidelines for establishing the bioequivalence of a formulation with a reference formulation have been published by the FDA Office of Generic Drugs, Division of Bioequivalence. 
     Two formulations whose PK parameters such as C max , AUC, or t max  differ by −20%/+25% or less are generally considered to be “bioequivalent”. Another approach for average bioequivalence involves the calculation of a 90% confidence interval for the ratio of the averages (population geometric means) of the measures for the test and reference products. To establish bioequivalence, the calculated confidence interval should fall within usually 80-125% for the ratio of the product averages. In addition to this general approach, the others approach, including (1) logarithmic transformation of pharmacokinetic data, (2) methods to evaluate sequence effects and (3) methods to evaluate outlier data, may be useful for the establishment of bioequivalence. For example, in the above (1) the confidence interval should fall within usually 80-125% for the difference in the mean value of the logarithmic converted PK parameter. 
     The term “dosage form(s)” shall mean the means to administer the drug substance (active pharmaceutical ingredient (API)), or to facilitate dosing, administration, and delivery of the medicine to the patient and other mammals Dosage forms are classified in terms of administration routes and application sites, including, for example, oral, topical, rectal, vaginal, intravenous, subcutaneous, intramuscular, ophthalmic, nasal, otic and inhalation administration. Alternatively, dosage forms are classified in terms of physical form such as solid, semi-solid or liquid. Furthermore, dosage forms are subdivided based on their form, functions and characteristics, including, without limited, tablet, capsule or injection as described in monograph of Japanese Pharmacopoeia 16 edition (JP16) or General Chapter &lt;1151&gt; Pharmaceutical Dosage Forms of U.S. Pharmacopoeia-NF (37)(USP37). 
     The term “excipient” shall mean a typically inactive ingredient used as a vehicle (for example, water, capsule shell etc.), a diluent, or a component to constitute a dosage form or pharmaceutical composition comprising a drug such as a therapeutic agent. The term also encompasses a typically inactive ingredient that imparts cohesive function (i.e. binder), disintegrating function (i.e. disintegrator), lubricant function (lubricating agent), and/or the other function (i.e. solvent, surfactant etc.) to the composition. 
     The term “a mean” refers to an arithmetical mean. The pharmacokinetic parameters such as “a mean C max ” or “a mean AUC” refer to the arithmetical mean value of a C max  or an AUC. 
     The list of the abbreviations and definitions of the terms used in this application is presented the following.
     AUC: Area under the plasma concentration-time curve   AUC (0-t) : Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration
       AUC (0-inf) : Area under the plasma concentration-time curve from time zero to infinite time   CL/F: Apparent total clearance following extravascular (e.g., oral) administration   C max : Maximum observed concentration   t 1/2 : Terminal elimination half-life   t max : Time to reach maximum (peak) concentration following drug administration   Vz/F: Apparent volume of distribution at terminal phase   
       

     The term “about”, unless otherwise indicated, refers to a value that is no more than 10% above or below the value being modified by the term. For example, the term “about 30 mg” means a range of from 27 mg to 33 mg. 
     The amount of Compound A or a pharmaceutically acceptable salt thereof contained in the oral dosage form is represented as the amount of Compound A in free form. For example, the term “an oral dosage form comprising about 30 mg of Compound A or a pharmaceutically acceptable salt thereof” means that the oral dosage form comprises Compound A or a pharmaceutically acceptable salt thereof equivalent to about 30 mg of Compound A in free form. When the oral dosage form is in the form of a dosage unit containing a particular amount of Compound A or a pharmaceutically acceptable salt thereof such as tablet and capsule, one or more dosage units may provide the amount of Compound A or a pharmaceutically acceptable salt thereof contained in the oral dosage form. For example, the term “an oral dosage form comprising about 30 mg of Compound A or a pharmaceutically acceptable salt thereof” means that the amount of Compound A or a pharmaceutically acceptable salt thereof contained in one dosage unit may be about 30 mg or that the amount of Compound A or a pharmaceutically acceptable salt thereof in two or more dosage unit may be about 30 mg in total. 
     II. Description of the Embodiments 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 2.3×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 3.9×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.1×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 64 ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound A of from about 13 ng/mL to about 5.5×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound A of from about 13 ng/mL to about 3.8×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound B of from about 12 ng/mL to about 1.6×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound B of from about 12 ng/mL to about 1.1×10 2  ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL after administration to human subjects. 
     In one embodiment, the present invention provides an oral dosage form comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 2.3×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 3.9×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 64 ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at a single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound A of from about 13 ng/mL to about 5.5×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound A of from about 13 ng/mL to about 3.8×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound B of from about 12 ng/mL to about 1.6×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean C max  of said Compound B of from about 12 ng/mL to about 1.1×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising about 30 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said oral dosage form at repeated once-daily doses achieves a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 2.3×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 3.9×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.1×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 64 ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound A of from about 13 ng/mL to about 5.5×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound A of from about 13 ng/mL to about 3.8×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound B of from about 12 ng/mL to about 1.6×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound B of from about 12 ng/mL to about 1.1×10 2  ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL after administration to human subjects. 
     In another embodiment, the present invention provides an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean C max  of said Compound A of from about 28 ng/mL to about 2.3×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer, or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer, or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer, or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 3.9×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean C max  of said Compound B of from about 19 ng/mL to about 64 ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer, or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer, or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves a mean AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound A of from about 13 ng/mL to about 5.5×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound A of from about 13 ng/mL to about 3.8×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound B of from about 12 ng/mL to about 1.6×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound B of from about 12 ng/mL to about 1.1×10 2  ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL after administration to human subjects. 
     In further embodiment, the present invention provides an oral dosage form for treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves C max  of said Compound A of from about 28 ng/mL to about 3.5×10 2  ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves C max  of said Compound A of from about 28 ng/mL to about 2.3×10 2  ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-t)  of said Compound A of from about 2.2×10 2  h*ng/mL to about 3.9×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.1×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-inf)  of said Compound A of from about 2.3×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves C max  of said Compound B of from about 19 ng/mL to about 1.0×10 2  ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves C max  of said Compound B of from about 19 ng/mL to about 64 ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-t)  of said Compound B of from about 2.7×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is single daily dose of about 30 mg to about 140 mg, and said single daily dose achieves AUC (0-inf)  of said Compound B of from about 2.9×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL after administration to the human subject. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound A of from about 13 ng/mL to about 5.5×10 2  ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound A of from about 13 ng/mL to about 3.8×10 2  ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.5×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound A of from about 1.6×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound B of from about 12 ng/mL to about 1.6×10 2  ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean C max  of said Compound B of from about 12 ng/mL to about 1.1×10 2  ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL after administration to human subjects. 
     In yet another embodiment, the present invention provides a method of treating stomach cancer, lung cancer, bladder cancer, endometrial cancer, bile duct cancer or breast cancer, comprising administering orally to a human subject in need thereof, an oral dosage form comprising a therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein said therapeutically effective amount is repeated once-daily doses of about 30 mg to 140 mg, and said repeated once-daily doses achieve a mean AUC (0-t)  of said Compound B of from about 1.9×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In the present invention, the oral dosage form may comprise about 30 mg to about 140 mg, about 35 mg to about 140 mg, about 60 mg to about 140 mg, about 70 mg to about 140 mg, about 100 mg to about 140 mg, or 105 mg to about 140 mg of Compound A or a pharmaceutically acceptable salt thereof. In the present invention, the therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof may be single daily dose of about 30 mg to about 140 mg, about 35 mg to about 140 mg, about 60 mg to about 140 mg, about 70 mg to about 140 mg, about 100 mg to about 140 mg, or 105 mg to about 140 mg. In the present invention, the therapeutically effective amount of Compound A or a pharmaceutically acceptable salt thereof may be repeated once-daily doses of about 30 mg to about 140 mg, about 35 mg to about 140 mg, about 60 mg to about 140 mg, about 70 mg to about 140 mg, about 100 mg to about 140 mg, or 105 mg to about 140 mg. 
     In the present invention, the oral dosage form at a single daily dose may achieve a mean C max  of said Compound A of from about 34 ng/mL to about 3.5×10 2  ng/mL, or from about 55 ng/mL to about 3.5×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean C max  of said Compound A of from about 38 ng/mL to about 2.3×10 2  ng/mL, or from about 85 ng/mL to about 2.3×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-t)  of said Compound A of from about 2.7×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL, or from about 6.0×10 2  h*ng/mL to about 7.2×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-t)  of said Compound A of from about 5.3×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL, or from about 1.0×10 3  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-t)  of said Compound A of from about 5.2×10 2  h*ng/mL to about 3.9×10 3  h*ng/mL, or from about 1.0×10 3  h*ng/mL to about 3.9×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-inf)  of said Compound A of from about 3.0×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL, or from about 6.4×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-inf)  of said Compound A of from about 3.1×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL, or from about 6.3×10 2  h*ng/mL to about 7.4×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-inf)  of said Compound A of from about 5.5×10 2  h*ng/mL to about 4.1×10 3  h*ng/mL, or from about 1.1×10 3  h*ng/mL to about 4.1×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-inf)  of said Compound A of from about 5.5×10 2  h*ng/mL to about 4.0×10 3  h*ng/mL, or from about 1.1×10 3  h*ng/mL to about 4.0×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean C max  of said Compound B of from about 16 ng/mL to about 1.0×10 2  ng/mL, or from about 34 ng/mL to about 1.0×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean C max  of said Compound B of from about 35 ng/mL to about 64 ng/mL, or from about 38 ng/mL to about 64 ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-t)  of said Compound B of from about 3.0×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL, or from about 4.9×10 2  h*ng/mL to about 1.6×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-t)  of said Compound B of from about 6.5×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL, or from about 6.4×10 2  h*ng/mL to about 1.4×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-inf)  of said Compound B of from about 3.3×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL, or from about 5.3×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at a single daily dose may achieve a mean AUC (0-inf)  of said Compound B of from about 6.8×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL, or from about 6.9×10 2  h*ng/mL to about 1.5×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean C max  of said Compound A of from about 50 ng/mL to about 5.5×10 2  ng/mL, or from about 1.1×10 2  ng/mL to about 5.5×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean C max  of said Compound A of from about 50 ng/mL to about 3.8×10 2  ng/mL, or from about 1.1×10 2  ng/mL to about 3.8×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean AUC (0-t)  of said Compound A of from about 4.9×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL, or from about 9.1×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean AUC (0-t)  of said Compound A of from about 5.0×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL, or from about 9.0×10 2  h*ng/mL to about 8.1×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean AUC (0-t)  of said Compound A of from about 4.9×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL, or from about 1.3×10 3  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean AUC (0-t)  of said Compound A of from about 5.0×10 2  h*ng/mL to about 4.7×10 3  h*ng/mL, or from about 1.3×10 3  h*ng/mL to about 4.7×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean C max  of said Compound B of from about 44 ng/mL to about 1.6×10 2  ng/mL, or from about 40 ng/mL to about 1.6×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean C max  of said Compound B of from about 44 ng/mL to about 1.1×10 2  ng/mL, or from about 55 ng/mL to about 1.1×10 2  ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean AUC (0-t)  of said Compound B of from about 5.6×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL, or from about 7.0×10 2  h*ng/mL to about 2.1×10 3  h*ng/mL after administration to human subjects. 
     In present invention, the oral dosage form at repeated once-daily doses may achieve a mean AUC (0-t)  of said Compound B of from about 5.6×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL, or from about 8.0×10 2  h*ng/mL to about 1.7×10 3  h*ng/mL after administration to human subjects. 
     In present invention, Compound A can be prepared by a method known in the art, such as US 2014-235614 and WO/2016/152907. 
     Pharmaceutically acceptable salts may include, but are not limited to, inorganic acid salts; organic carboxylates; organic sulfonates; amino acid salts; quaternary amine salts; alkaline metal salts; and alkaline-earth metal salts. Preferred pharmaceutically acceptable salts include succinate such as 1.5 succinate. 
     Oral dosage forms of the present invention include capsules, granules, lozenges, pellets, pills, powders, suspensions, tablets, preferably capsules, granules, pellets, pills, tablets. 
     The oral dosage form of the present invention may be prepared, using standard techniques and manufacturing processes generally known in the art. See, e.g. the monograph of Japanese Pharmacopoeia 16 edition or General Chapter &lt;1151&gt; Pharmaceutical Dosage Forms of U.S. Pharmacopoeia-NF (37). 
     EXAMPLES 
     The following examples illustrate various aspects of the present invention. They are not to be construed to limit the claims in any manner whatsoever. 
     Compound A 1.5 succinate was synthesized according to the method described in WO/2016/152907. 
     The following study was carried out in order to evaluate tolerability and safety when Compound A 1.5 succinate was orally administered to patients with solid tumor. We attempted to determine the maximum tolerated dose (MTD) by evaluating the dose limiting toxicity (DLT) when Compound A 1.5 succinate was orally administered to patients with solid tumor. Each dose in Examples is represented as a dose of Compound A in free form. 
     Methods 
     A Modified Toxicity Probability Interval (mTPI) design was employed to determine the MTD of Compound A. Each subject was assigned a dose of Compound A in accordance with the rules of the mTPI design based on a target dose-limiting toxicity (DLT) rate of 25% and the corresponding three toxicity probability intervals that was defined as 20 to 30% (proper dosing), 0 to 20% (underdosing) and 30 to 100% (overdosing). The entire dose assignment decision rule can be precalculated under the mTPI design and presented in two-way table as below. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Decision Rule for Dose Assignment 
               
            
           
           
               
               
            
               
                   
                 Number of Subjects Treated at the Current Dose 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                 2 
                 4 
                 6 
                 8 
                 10 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Number 
                 0 
                 E 
                 E 
                 E 
                 E 
                 E 
               
               
                 of 
                 1 
                 D a   
                 S 
                 S 
                 E 
                 E 
               
               
                 Subjects 
                 2 
                 D, U 
                 D 
                 S 
                 S b   
                 S 
               
               
                 with 
                 3 
                   
                 D, U 
                 D 
                 S 
                 S b   
               
               
                 DLT 
                 4 
                   
                 D, U 
                 D, U 
                 D, U 
                 S 
               
               
                   
                 5 
                   
                   
                 D, U 
                 D, U 
                 D, U 
               
               
                   
               
               
                 E = Escalate to the next higher dose, 
               
               
                 S = Stay at the current dose, 
               
               
                 D = De-escalate to the next lower dose, 
               
               
                 U = current dose is unacceptably toxic (i.e., Do not re-enter the current dose) 
               
               
                 Target DLT rate at MTR = 25% and its equivalence toxicity interval = 20 to 30%. Cohort size = 2 subjects 
               
               
                 Display for more than 10 subjects at the current dose is omitted 
               
               
                   a Extra subjects may be added for the starting dose. 
               
               
                   b Early closure of registration may be considered. 
               
            
           
         
       
     
     Administration Schedule 
     1) Cycle 0 (for 7 days) 
     In order to evaluate the PK when administered as a single dose, a single dose of Compound A for each treatment group (at the corresponding dosage for that group) was administered on Day 1. Compound A was administered when fasted, immediately after waking up with at least 10 hours fasting. Taking any meal was prohibited for 2 hours after administration and only drinking water was allowed. 
     2) Cycle 1 or later (28 day cycles) 
     Cycle 1 was started between 8 and 10 days after dosing in Cycle 0 and Compound A was administered continuously once daily. Compound A was administered at least 2 hours after breakfast, and any food intake was prohibited for 1 hour after administration. However, on Day 8 of Cycle 1, Compound A was administered immediately after waking up while the subject was fasted after at least 10 hours of overnight fasting in order to evaluate the PK. Taking any meals was prohibited for 2 hours after administration and only drinking water was allowed. 
     Setting of Starting Dose 
     The starting dose of Compound A in this study was set based on the guidelines in “Nonclinical Evaluation for Anticancer Pharmaceuticals” (ICH S9; PFSB/ELD Notification No. 0604-1, dated Jun. 4, 2010). According to this guideline, a common approach for many small-molecules is to set a starting dose at 1/10 the Severely Toxic Dose in 10% of the animals (STD 10; dose that is associated with lethality, life-threatening toxicities, or irreversible toxicities) in rodents, or at ⅙ the Highest Non-Severely Toxic Dose (HNSTD) in the case where non-rodents are the most appropriate test species. Considering subject safety, the 1.46 mg dose that was calculated from toxicity studies in rats (which are highly sensitivity to toxicity) was thus adopted and the starting dose in this study was set as 1 mg, a dose below the 1.46 mg dose. 
     Inclusion Criteria 
     
         
         
           
             (1) Subjects age&gt;=20 years at the time of informed consent 
             (2) Subjects with a histological and/or cytological diagnosis of solid tumor 
             (3) Subjects who failed standard therapies, or for which no appropriate treatment is available. 
             (4) Corrected serum calcium&lt;=ULN 
             (5) Serum phosphate&lt;=ULN 
             (6) Subjects with Performance Status (PS) score of 0-1 established by Eastern Cooperative Oncology Group (ECOG) 
           
         
       
    
     Exclusion Criteria 
     
         
         
           
             (1) Subjects with brain metastasis that is associated with clinical symptoms or require treatment 
             (2) Medical history of clinically significant cardiovascular impairment 
             (3) Current evidence or history of corneal disorder&gt;=Grade 2 
           
         
       
    
     DLT Criteria 
     
         
         
           
             (1) Grade 4 neutropenia that persists for more than 7 days or febrile neutropenia 
             (2) Grade 4 thrombocytopenia or Grade 3 thrombocytopenia that requires blood transfusion 
             (3) Any Grade 3 or higher non-hematological toxicity with the exception of:
           a) Abnormal clinical laboratory values with no clinical significance.   b) Any events which can be managed and controlled to Grade 2 or less by maximal medical management.   
         
             (4) New calcification that is considered clinically significance in such as soft tissue, kidney, intestine, heart or lung confirmed by images 
             (5) Hyperphosphatemia defined as follows
           a) &gt;7 mg/dL&gt;7d despite phosphate lowering therapies   b) &gt;9 mg/dL despite phosphate lowering therapies.   
         
             (6) Development of any toxicity that is considered to be related to Compound A and where treatment interruption for 8 days or more from Cycle 0 to Cycle 1 is necessary. 
           
         
       
    
     Results 
     Patient Characteristics 
       
     
       
         
           
               
               
             
               
                   
                 TABLE 2 
               
               
                   
                   
               
               
                   
                 No. of 
               
               
                   
                 Subjects 
               
               
                   
                 (%) 
               
               
                   
                 (N = 24) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Age, Years 
                 Median 
                 65 
               
               
                   
                   
                 Range 
                 42-75 
               
            
           
           
               
               
               
               
               
            
               
                   
                 Gender 
                 Male 
                 11 
                 (46) 
               
               
                   
                   
                 Female 
                 13 
                 (54) 
               
               
                   
                 ECOG-PS 
                 0 
                 17 
                 (71) 
               
               
                   
                   
                 1 
                 7 
                 (29) 
               
               
                   
                 No. of prior 
                 ≤2 
                 9 
                 (38) 
               
               
                   
                 chemotherapy 
                 ≥3 
                 15 
                 (63) 
               
               
                   
                 Cancer type 
                 Cholangiocarcinoma 
                 8 
                 (33) 
               
               
                   
                   
                 Pancreatic cancer 
                 3 
                 (13) 
               
               
                   
                   
                 Endometrial cancer 
                 2 
                 (8) 
               
               
                   
                   
                 Cancer of unknown primary 
                 2 
                 (8) 
               
               
                   
                   
                 Other 
                 9 
                 (38) 
               
               
                   
                   
               
            
           
         
       
     
     Summary of Dose Escalation Study 
     Among the patients treated with once-daily dosing of Compound A: 1 mg (2 patients), 2 mg (2 patients), 4 mg (2 patients), 8 mg (2 patients), 16 mg (2 patients), 30 mg (2 patients), 60 mg (3 patients), 100 mg (3 patients), 140 mg (3 patients) and 180 mg (3 patients), one patient at 180 mg dosing experienced the DLT (Grade 3 AST/ALT increased). The MTD was not defined and the recommended dose was determined to be 140 mg once daily. 
     Treatment emergent adverse events (&gt;=5%) are as shown in the following table. 
     
       
         
           
               
               
               
               
               
               
               
             
               
                   
                 TABLE 3 
               
             
            
               
                   
                   
               
               
                   
                 1-30 mg 
                 60 mg 
                 100 mg 
                 140 mg 
                 180 mg 
                 Total 
               
               
                   
                 (N = 12) 
                 (N = 3) 
                 (N = 3) 
                 (N = 3) 
                 (N = 3) 
                 (N = 24) 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                 Any 
                   
                 Any 
                   
                 Any 
                   
                 Any 
                   
                 Any 
                   
                 Any 
                   
               
               
                 Toxicities 
                 Gr 
                 ≥Gr3 
                 Gr 
                 ≥Gr3 
                 Gr 
                 ≥Gr3 
                 Gr 
                 ≥Gr3 
                 Gr 
                 ≥Gr3 
                 Gr 
                 ≥Gr3 
               
               
                   
               
               
                 Hyperphosphatemia 
                 — 
                 — 
                 — 
                 — 
                  3 (100) 
                 — 
                  3 (100) 
                 — 
                  3 (100) 
                 — 
                 9 (38) 
                 — 
               
               
                 Creatinine 
                  2 (17) 
                 — 
                 2 (67) 
                 — 
                 1 (33) 
                 — 
                  3 (100) 
                 — 
                 1 (33) 
                 — 
                 9 (38) 
                 — 
               
               
                 increased 
               
               
                 ATL 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                  3 (100) 
                 — 
                 2 (67) 
                 2 (67) 
                 6 (25) 
                 2 (8) 
               
               
                 increased 
               
               
                 Diarrhoea 
                 1 (8) 
                 — 
                 2 (67) 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                  3 (100) 
                 — 
                 6 (25) 
                 — 
               
               
                 Lipase 
                 1 (8) 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 5 (21) 
                 — 
               
               
                 increased 
               
               
                 Nausea 
                 — 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 5 (21) 
                 — 
               
               
                 AST 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 2 (67) 
                 — 
                 2 (67) 
                 1 (33) 
                 4 (17) 
                 — 
               
               
                 increased 
               
               
                 PPE 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 2 (67) 
                 — 
                 4 (17) 
                 — 
               
               
                 syndrome 
               
               
                 ALP 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 2 (67) 
                 — 
                 — 
                 — 
                 3 (13) 
                 — 
               
               
                 increased 
               
               
                 Anaemia 
                 — 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 3 (13) 
                 — 
               
               
                 Dysgeusia 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 2 (67) 
                 — 
                 1 (33) 
                 — 
                 3 (13) 
                 — 
               
               
                 Retinal 
                 — 
                 — 
                 — 
                 — 
                 2 (67) 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 3 (13) 
                 — 
               
               
                 detachment 
               
               
                 Vomiting 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 1 (33) 
                 3 (13) 
                 1 (4) 
               
               
                 Constipation 
                 1 (8) 
                 — 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 2 (8)  
                 — 
               
               
                 Decreased 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 1 (33) 
                 2 (8)  
                 1 (4) 
               
               
                 appetite 
               
               
                 Lymphocyte 
               
               
                 count 
                 — 
                 — 
                 1 (33) 
                 1 (33) 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 2 (8)  
                 — 
               
               
                 decreased 
               
               
                 Malaise 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 2 (8)  
                 — 
               
               
                 Neutrophil 
               
               
                 count 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 2 (67) 
                 1 (33) 
                 2 (8)  
                 1 (4) 
               
               
                 decreased 
               
               
                 Onychomadesis 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 1 (33) 
                 — 
                 2 (8)  
                 — 
               
               
                 Stomatitis 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 2 (8)  
                 — 
               
               
                 White 
                 — 
                 — 
                 1 (33) 
                 — 
                 — 
                 — 
                 — 
                 — 
                 1 (33) 
                 — 
                 2 (8)  
                 — 
               
               
                 blood cell 
               
               
                 count 
               
               
                 decreased 
               
               
                   
               
            
           
         
       
     
     Serious adverse events were reported in 3 patients (dyspnoea in a patient in 8 mg cohort, tumor pain aggravation in a patient in 8 mg cohort and pyrexia in a patient at 30 mg cohort). However, none of them were considered to be related to Compound A. 
     No death or adverse events leading to study drug withdrawal were reported. 
     The adverse events leading to dose reductions were ALT increased (2 patients), palmar-plantar erythrodysesthesia syndrome (2 patients) and AST increased (1 patient). 
     The adverse events leading to dose interruptions were nausea (3 patients), vomiting (2 patients), anorexia (2 patients), pyrexia (2 patients), common cold (1 patient), neutrophil count decreased (1 patient), macular edema (1 patient) and palmar-plantar erythrodysesthesia syndrome (1 patient). 
     Pharmacokinetics 
     Plasma concentration profile of Compound A following a single dose and repeated doses of Compound A 1.5 succinate are shown in  FIG. 1  and  FIG. 2 , respectively. The profile shown in  FIG. 2  is that at steady state. 
     The pharmacokinetic parameters of Compound A following the single dose and repeated doses of Compound A 1.5 succinate are shown in the following table. The pharmacokinetic parameters of Compound A following repeated doses of Compound A 1.5 succinate shown below are those at steady state. 
     
       
         
           
               
               
               
               
               
               
             
               
                   
                 TABLE 4 
               
               
                   
                   
               
               
                   
                 30 mg 
                 60 mg 
                 100 mg 
                 140 mg 
                 180 mg 
               
               
                   
                 (n = 2) 
                 (n = 3) 
                 (n = 3) 
                 (n = 3) 
                 (n = 3) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
            
               
                 Single 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 t 1/2   
                 (h) 
                 22.8 
                 23.1 ± 7.65 
                 15.1 ± 1.77 
                 26.4 ± 12.2 
                 23.6 ± 10.2 
               
               
                 t max   
                 (h) 
                 3 (1-5) 
                 3 (3-5) 
                 5 (3-5) 
                 5 (3-5) 
                 2 (2-5) 
               
               
                 C max   
                 (ng/mL) 
                 28.1 
                 38.7 ± 4.69 
                 85.9 ± 30.8 
                     227 ± 118.0 
                  154 ± 38.4 
               
               
                 AUC (0-t)   
                 (h · ng/mL) 
                 220 
                 529 ± 250 
                 1090 ± 483  
                 3900 ± 3230 
                 2540 ± 924  
               
               
                 AUC (0-inf)   
                 (h · ng/mL) 
                 236 
                 551 ± 240 
                 1120 ± 488  
                 4000 ± 3340 
                 2570 ± 907  
               
               
                 Vz/F 
                 (L) 
                 4230 
                 3820 ± 1280 
                 2310 ± 1370 
                 1700 ± 650  
                 2560 ± 1490 
               
               
                 CL/F 
                 (L/h) 
                 128 
                  122 ± 42.5 
                  103 ± 48.9 
                 60.4 ± 51.6 
                 75.0 ± 22.0 
               
            
           
           
               
            
               
                 Repeat 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 t max   
                 (h) 
                 4 (3-5) 
                 2.5 (2-3) a   
                 3 (2-5) 
                 5 (3-5) 
                 5 (3-5) 
               
               
                 C max   
                 (ng/mL) 
                 13.3 
                 50.5 a   
                  116 ± 3.79 
                 372 ± 173 
                  337 ± 60.3 
               
               
                 AUC (0-t)   
                 (h · ng/mL) 
                 158 
                 499 a        
                 1330 ± 417  
                 4700 ± 3380 
                 3850 ± 777  
               
               
                 C min   
                 (ng/mL) 
                 2.48 
                  8.28 a   
                 18.7 ± 7.95 
                  101 ± 94.5 
                 61.4 ± 19.9 
               
               
                 C avg   
                 (ng/mL) 
                 6.58 
                 20.8 a   
                 55.2 ± 17.3 
                 196 ± 141 
                  161 ± 32.3 
               
               
                   
               
               
                   a n = 2 
               
               
                 Cmax and AUC increased with increasing dose with tmax of 2-5 hr and mean t½ of 15.1-26.4 hr. 
               
            
           
         
       
     
     The pharmacokinetic parameters of Compound A following the single dose and repeated doses of Compound A 1.5 succinate updated after obtaining the above data are shown in the following table. The pharmacokinetic parameters of Compound A following repeated doses of Compound A 1.5 succinate shown below are those at steady state. 
     
       
         
           
               
               
               
               
               
               
             
               
                   
                 TABLE 5 
               
               
                   
                   
               
               
                   
                 30 mg 
                 60 mg 
                 100 mg 
                 140 mg 
                 180 mg 
               
               
                   
                 (n = 2) 
                 (n = 3) 
                 (n = 3) 
                 (n = 3) 
                 (n = 3) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
            
               
                 Single 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 t 1/2   
                 (h) 
                 22.7 
                 23.1 ± 7.63 
                 15.2 ± 1.84 
                 26.4 ± 12.4 
                 23.7 ± 10.4 
               
               
                 t max   
                 (h) 
                 3.04 (0.93-5.15) 
                 3.00 (2.97-4.98)      
                 4.95 (2.97-5.10) 
                 4.88 (3.00-5.08) 
                 2.12 (1.95-5.00) 
               
               
                 C max   
                 (ng/mL) 
                 28.1 
                 38.7 ± 4.69 
                 85.9 ± 30.8 
                 227 ± 118 
                  154 ± 38.4 
               
               
                 AUC (0-t)   
                 (h · ng/mL) 
                 222 
                 533 ± 257 
                 1080 ± 474  
                 3960 ± 3230 
                 2570 ± 933  
               
               
                 AUC (0-inf)   
                 (h · ng/mL) 
                 239 
                 554 ± 247 
                 1120 ± 479  
                 4050 ± 3340 
                 2610 ± 921  
               
               
                 Vz/F 
                 (L) 
                 4180 
                 3790 ± 1240 
                 2310 ± 1360 
                 1670 ± 617  
                 2550 ± 1500 
               
               
                 CL/F 
                 (L/h) 
                 127 
                  121 ± 43.1 
                  103 ± 48.2 
                 59.0 ± 50.2 
                 74.2 ± 21.8 
               
            
           
           
               
            
               
                 Repeat 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 t max   
                 (h) 
                 3.99 (3.00-4.97) 
                 2.54 (2.07-3.00)  a   
                 2.97 (2.03-5.00) 
                 5.00 (2.98-5.08) 
                 5.00 (3.05-5.08) 
               
               
                 C max   
                 (ng/mL) 
                 13.3 
                 50.5 a   
                  116 ± 3.79 
                 372 ± 173 
                  337 ± 60.3 
               
               
                 AUC (0-t)   
                 (h · ng/mL) 
                 162 
                 507 a        
                 1340 ± 437  
                 4700 ± 3380 
                 3860 ± 764  
               
               
                 C min   
                 (ng/mL) 
                 4.50 
                 11.0 a   
                 22.3 ± 8.48 
                 117 ± 116 
                 64.8 ± 19.4 
               
               
                 C avg   
                 (ng/mL) 
                 6.75 
                 21.1 a   
                 55.91 ± 8.2  
                 196 ± 141 
                  161 ± 32.3 
               
               
                   
               
               
                 Data is shown as mean ± SD except for tmax; for tmax, median (minimum − maximum) is shown. 
               
               
                 PK prameters were calculated by NCA method using prompt results for plasma concentrations, nominal time. 
               
               
                 Cmax and AUC increased with increasing dose with median tmax of 2-5 hrs and mean t½ of 15.2-26.6 hrs. 
               
               
                   a n = 2 
               
            
           
         
       
     
     The pharmacokinetic parameters of Compound B following the single dose and repeated doses of Compound A 1.5 succinate are shown in the following table. The pharmacokinetic parameters of Compound B following repeated doses of Compound A 1.5 succinate shown below are those at steady state. 
     
       
         
           
               
               
               
               
               
               
             
               
                   
                 TABLE 6 
               
               
                   
                   
               
               
                   
                 30 mg 
                 60 mg 
                 100 mg 
                 140 mg 
                 180 mg 
               
               
                   
                 (n = 2) 
                 (n = 3) 
                 (n = 3) 
                 (n = 3) 
                 (n = 3) 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
            
               
                 Single 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 t 1/2   
                 (h) 
                 21.5 
                 26.1 ± 10.2 
                  20.0 ± 0.794 
                 40.50 ± 6.46 
                 39.9 ± 6.27 
               
               
                 t max   
                 (h) 
                 3.59 (2.02-5.15) 
                 4.98 (3.00-5.07) 
                 4.95 (2.97-5.10) 
                 5.00 (4.88-5.08) 
                 5.00 (3.00-5.02) 
               
               
                 C max   
                 (ng/mL) 
                 19.2 
                 35.1 ± 19.1 
                 38.4 ± 4.36 
                  63.8 ± 36.1 
                 50.7 ± 20.7 
               
               
                 AUC (0-t)   
                 (h* ng/mL) 
                 274 
                 652 ± 352 
                 647 ± 153 
                 1350 ± 233 
                 1320 ± 693  
               
               
                 AUC (0-inf)   
                 (h* ng/mL) 
                 297 
                 687 ± 354 
                 699 ± 163 
                 1410 ± 216 
                 1370 ± 703  
               
            
           
           
               
            
               
                 repeated 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 t max   
                 (h) 
                 3.49 (1.97-5.00) 
                 2.54 (2.07-3.00)  a   
                 5.00 (4.98-5.05) 
                 5.00 (2.98-5.08) 
                 5.00 (3.05-5.08) 
               
               
                 C max   
                 (ng/mL) 
                 12.4 
                 44.2  a   
                 55.4 ± 14.5 
                     106 ± 51.8 
                 98.0 ± 39.5 
               
               
                 AUC (0-t)   
                 (h* ng/mL) 
                 194 
                 565  a        
                 805 ± 195 
                 1620 ± 460 
                 1500 ± 686  
               
               
                 C min   
                 (ng/mL) 
                 5.19 
                 12.3  a   
                 17.4 ± 7.37 
                  41.5 ± 10.9 
                 32.8 ± 13.0 
               
               
                 C avg   
                 (ng/mL) 
                 7.71 
                 22.6  a   
                 32.3 ± 7.79 
                  66.1 ± 18.8 
                 60.4 ± 27.7 
               
               
                   
               
               
                 Data is shown as mean ± SD except t max ; for t max  median (minimum − maximum) is shown. 
               
               
                   a  n = 2 
               
            
           
         
       
     
     Anti-Tumor Activity 
     Compound A was administered once daily at 180 mg to a patient (45 years-old woman) with FGFR2 gene amplified diffused type gastric cancer (poorly differentiated adenocarcinoma). CT images of the patient are shown in  FIG. 3 . The left image is that before the administration and the right image is that on Day 1 of Cycle 3. The tumor size reduced significantly by the administration of Compound A. 
     When Compound A was administered once daily at 30 mg to a patient with FGFR2-fusion gene positive (78%) intrahepatic cholangiocarcinoma, the tumor size reduced by about 9%. 
     Pharmacodynamics (PD) 
     Serum concentrations of Phosphate, FGF23 and 1,25-(OH) 2 -Vitamin D, PD markers of FGFR pathway inhibition were measured before the administration of Compound A and on Day 15 of Cycle 1. Changes in concentration during administration of Compound A were shown in  FIG. 4 . The administration of Compound A induced dose-dependent increases in each marker, and these increases reached maximum at approximately 100-140 mg once-daily dosing.